Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Asterias
- Development stage
- Preclinical
- Lead developer
- Aphios
- Modality
- Nanoparticles → Drug Delivery Systems
- Administration
- Topical
01
Overview
Asterias is a botanical nanoformulation being developed by Aphios Corporation for the treatment and prevention of oral diseases, including gingivitis, dental caries, and periodontitis. Discovered through the screening of marine microorganisms against pathogens responsible for oral infections, Asterias acts as an anti-plaque agent by targeting oral bacteria and disrupting the formation of biofilms. The formulation utilizes Aphios's proprietary nanotechnology to deliver marine-derived active ingredients effectively to the site of infection. It is currently in the preclinical stage of development.
- Brand names
- Asterias
Beyond the preview
Go deeper on Asterias.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Asterias.